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THE influence of circulating serotonin (5-HT) on the
effects of intra-articular administration of granise-
tron on temporomandibular joint (TMJ) pain was
investigated in 11 patients with chronic polyarthri-
tides. An analgesic effect superior to placebo has
been shown previously.
The change in TMJ movement pain intensity was
negatively correlated to circulating 5-HT; that is, the
higher the 5-HT before injection, the greater the
reduction of pain intensity. The resting pain intensity
reduction was not related to 5-HT.
In conclusion, this study indicates a stronger short-
term analgesic effect on TMJ movement pain by intra-
articular administration of the 5-HT3 receptor antago-
nist granisetron in patients with high levels of
circulating 5-HT.
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Introduction
Temporomandibular joint (TMJ) pain is a significant
part of the symptomatology and impairment of daily
life in patients with TMJ involvement of chronic
polyarthritides such as rheumatoid arthritis (RA).
1
The monoamine serotonin (5-HT) mediates pain and
hyperalgesia,
2 and has been found to be associated
with TMJ pain upon joint movement and associated
impairment of mobility.
3 Peripheral 5-HT is mainly
stored in thrombocytes, and several signal substances
involved in the mediation of inflammation can induce
5-HT release from these cells.
4,5 In patients with RA,
thrombocytes have been found to be increased in
number and to release 5-HT.
4 Richardson and Engel
showed that 5-HT participates in the mediation of
resting pain from inflamed peripheral tissues by
sensitizing or exciting fine afferent units via the
5-HT3 receptor.
6 This receptor is peripherally located
only on afferent neurons.
7 In a recent study of
patients with RA, intra-articular injection of 1 mg of
the 5-HT3 receptor antagonist granisetron was found
to reduce TMJ resting pain for at least 20 min and
injection of granisetron into the healthy human
masseter muscle reduced pain induced by local
administration of 5-HT.
8,9 It therefore seems probable
that the 5-HT3 receptor is involved in the modulation
of musculoskeletal pain. The analgesic effect of
granisetron most probably depends on the cell-sur-
face expression of 5-HT3 receptors on the local nerve
endings and on the local tissue level of 5-HT.
However, the influence of circulating 5-HT, which is
the major source of tissue 5-HT, on the response to
granisetron is unknown. The aim of this study was
therefore to investigate the influence of circulating
5-HT on the effects on TMJ pain by intra-articular
administration of granisetron in patients with chronic
polyarthritides.
Materials and methods
Patients
Eleven patients (10 females and one male) with a
median (interquartile range) age of 40 (22) years with
signs (localized pain) of TMJ involvement by chronic
polyarthritides were included (Table 1). The diag-
nosis of RA (three patients) was determined accord-
ing to the 1987 classification criteria of the American
College of Rheumatology,
10 while the diagnosis of
psoriatic arthritis (one patient), ankylosing spondyli-
tis (one patient), reactive polyarthritis (two patients),
Sjo ¨gren’s syndrome (one patient) or chronic unspe-
cific polyarthritis (three patients) was determined
according to the European Spondylarthropathy Study
Group’s criteria.
11
The patients were first referred to the Department
of Rheumatology at the University of Tartu, Estonia
from general practitioners or rheumatologists in
Estonia. After an inclusion examination at the rheu-
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373matology clinic, the patients were referred to the
Department of Stomatology at the same university.
Inclusion criteria were diagnosis of chronic polyar-
thritis, resting pain localized to the TMJ region
and a reduction in TMJ pain intensity upon maxi-
mum mouth opening of 35% or more after an
auriculotemporal nerve block with 2 ml of 2%
lidocaine (20 mg/ml of Xylocain; Astra-Zeneca,
So ¨derta ¨lje, Sweden). Exclusion criteria were preg-
nancy and allergic reactions to granisetron or any
other disease that may cause pain in the TMJ region.
All patients used non-steroid anti-inflammatory
drugs, three patients used oral glucocorticoids and
three patients used disease-modifying antirheumatic
drugs. The patients had not been subjected to any
recent (B /3 months) treatment of the TMJ. The study
was approved by the local ethics committees at the
University of Tartu, Estonia (94/3, 01) and the
Huddinge University Hospital, Sweden (151/01). All
individuals gave their verbal consent.
Procedures
After the inclusion examination, the current resting
pain intensity and the pain intensity during maximum
mouth opening of the TMJ were assessed with a 100
mm visual analogue scale (ACO, Stockholm, Sweden)
with end-points marked ‘No pain’ and ‘Worst pain
ever experienced’. The pain intensities were assessed
before the injection as well as at every fifth minute
during the first 30 min and then every 10th min up to
60 min. Three ml of the 5-HT3 antagonist granisetron
(1 mg/ml of Kytril†; F. Hoffman-La Roche Ltd, Basel,
Switzerland) was used for the injections. Granisetron
was administered into the posterior part of the upper
joint compartment of the most painful TMJ during
approximately 3 min. The patients were contacted
within 1 week after the granisetron injection to record
any adverse effect.
Venous blood was sampled prior to the injections
to measure the serum concentrations of 5-HT, rheu-
matoid factor, C-reactive protein, thrombocyte parti-
cle count and the erythrocyte sedimentation rate.
C-reactive protein concentrations below 10 mg/l and
rheumatoid factor concentrations below 20 IU/ml
were considered normal.
Analysis
Serotonin was analyzed by a commercially available
enzyme immunoassay kit (Immunotech, Marseille,
France) with a detection limit of 0.5 nmol/l and a
sensitivity of 0.5 nmol/l. The intra-assay coefficient of
variation for this assay is B /9.4% and the interassay
coefficient of variation is B /9.9% according to the
manufacturer. According to the manufacturer, the
normal concentration to be expected for 5-HT in
human serum is 300/700 nmol/l for males and 500/
900 nmol/l for females.
Statistics
The analgesic effect was expressed by the ratio
between the post-injection values of TMJ resting
pain and movement pain intensities, respectively,
and the corresponding pre-injection values. Fried-
man’s repeated-measures test and Dunn’s post-hoc
test for compensation of multiple comparisons were
used to calculate the significance of the change in
pain intensity during the experimental procedure.
The significance of correlations between blood vari-
ables, pre-injection pain intensities and effects of the
injections were tested by the Spearman ranked
correlation test. A probability level less than 0.05
was considered as significant.
Results
The serum concentration of 5-HT was above the
normal range in four patients (36%) and below it in
four patients (36%), while the thrombocyte particle
concentration was within the normal range for all
patients.
The serum concentration of 5-HT was negatively
correlated to the change in TMJ pain intensity upon
maximum mouth opening after 60 min (rs / /.72,
Table 1. Demographic and background factors in 11 patients
with chronic polyarthritides receiving injections of 3 mg/3 ml
of granisetron into the temporomandibular joint (TMJ)
Parameter Median Interquartile
range
Age (years) 40 22
Duration
a
General disease (years) 5 7
TMJ disease (years) 1 2
Pre-injection TMJ pain intensity
Rest
Injected side (VAS) 21 22
Contralateral side (VAS) 0 1
Maximum mouth opening
Injected side (VAS) 39 22
Contralateral side (VAS) 0 2
Background factors
Number of symptomatic joint
regions
32
Erythrocyte sedimentation rate
(mm/h)
16 26
C-reactive protein (mg/l) 5 12
Thrombocyte particle count
(10
9/l)
265 102
Rheumatoid factor (IU/ml) 0 0
Serotonin
Serum (nmol/l) 668 531
Plasma (nmol/l) 10 9
VAS, visual analogue scale.
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concentration of 5-HT before injection, the larger the
reduction of pain intensity. Such a relation was not
found for TMJ resting pain intensity and the serum
level of 5-HT (rs /0.06, n /11, p /0.852).
After the granisetron injection, a significant reduc-
tion of TMJ pain intensity was present during the
whole experimental period (resting pain intensity,
p /0.007; movement pain intensity, p /0.030) on the
injection side. Neither TMJ resting pain intensity nor
TMJ pain intensity upon maximum mouth opening
changed significantly on the non-injection side dur-
ing the observation time period.
The pre-injection levels of the inflammatory mar-
kers are presented in Table 1. The C-reactive protein
level correlated positively to the erythrocyte sedi-
mentation rate (rs /0.75, n /11, p /0.008) and to the
thrombocyte particle count (rs /0.86, n /11, p /
0.001), but did not influence the analgesic effect of
granisetron.
Age was positively correlated to the ratio between
TMJ pain intensity upon maximum mouth opening
after 60 min and the corresponding pre-injection pain
intensity (rs /0.62, n /11, p /0.041); that is, a larger
reduction of movement pain intensity was found
in the younger patients. Age and serum concentration
of 5-HT were not significantly correlated (rs / /0.24,
n /11, p /0.498).
The granisetron injections were well tolerated and
there were no adverse effects following the injection
during the experimental procedure or thereafter.
Discussion
This study indicates that the analgesic effect of intra-
articular administration of granisetron is influenced
by the level of circulating 5-HT in patients with
chronic polyarthritides.
A higher serum level of 5-HT was associated with a
stronger analgesic effect of granisetron on the pain
intensity upon maximum mouth opening, which is
interesting from three aspects: the anti-nociceptive
effect created by block of the 5-HT3 receptor, the fact
that the effect of granisetron seems to be specific for
reduction of movement pain intensity, and the
relation to serum 5-HT. It is thus very probable that
the effect of granisetron after intra-articular adminis-
tration can be contributed to a specific antagonism
of the 5-HT3 receptor. Richardson and Engel showed
that 5-HT participates in the mediation of sponta-
neous pain from inflamed peripheral tissues by
exciting or sensitizing fine afferent units by the
5-HT3 receptor.
6 Giordano and Rogers
12 found that
5-HT3 receptor antagonists had greater analgesic
effect on chronic pain than on acute pain in a
peripheral animal inflammation model, which indi-
cates the involvement of peripheral 5-HT3 receptor
sites in chronic inflammatory pain and supports our
findings about the 5-HT3 receptor.
Activation of the 5-HT3 receptor causes a long-
lasting sensitization even of high-threshold mechano-
sensitive units as well as a brief excitation of other
mechanosensitive units in joints.
13 Therefore, this
receptor type might be active to specifically elicit TMJ
movement pain; that is, pain due to mechanical
stimulation of the synovial tissues upon joint move-
ment by activation of mechanosensitive units.
Serum 5-HT, which is the main source for synovial
tissue 5-HT, has previously been found to modulate
inflammation and TMJ pain in patients with seropo-
sitive rheumatoid arthritis.
14 Increased serum and
plasma levels of 5-HT would probably cause an
immediate increase of the tissue 5-HT level, result-
ing in increased stimulation of peripheral 5-HT
receptors and, in turn, sensitization of nociceptors
in the synovial tissues by, for example, the 5-HT3
FIG. 1. Scatterplots of the relation between the serum
concentration of 5-HT and TMJ pain intensity (A) at rest
and (B) upon maximum mouth opening 60 min after intra-
articular injection of granisetron (3 mg/3 ml). The pain
intensities are shown normalized to the pre-injection level
(1.0). For TMJ pain upon maximum mouth opening there
was a negative correlation to 5-HT (rs / /0.72, n /11,
p /0.012), while no signiﬁcant correlation was found for
TMJ pain at rest (rs /0.06, n /11, p /0.852).
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4,79 Indeed, high synovial fluid levels of
5-HT in the TMJ have been associated with TMJ
movement pain.
3 It is therefore reason to assume that
granisetron has the possibility to produce a greater
analgesic effect by blocking 5-HT3 receptor binding
of 5-HT when there is a high 5-HT level in the serum
and synovial tissues, which could explain the relation
between serum 5-HT and the reduction of TMJ
movement pain intensity found in the present study.
The anti-nociceptive effect of the granisetron
injection found in this study could also, at least
partly, be due to an unspecific effect of the injection
or injection procedure per se. Examples of such
unspecific effects could be dilution of endogenous
pain mediators in the synovial tissues by the injected
solution and placebo effects. However, since the
analgesic effect was related to circulating 5-HT levels,
a specific analgesic effect of granisetron is likely.
In the present study, the effect of granisetron was
not related to the blood levels of inflammatory
markers, which suggests that the effect of granisetron
is not primarily influenced by disease activity. In
addition, the blood levels of inflammatory markers as
well as serotonin for the majority of patients were
below the upper normal limits, which means that the
patients can be considered to have a low inflamma-
tory disease activity. Whether there is a pain-relieving
effect of granisetron in more active disease is there-
fore so far unknown.
In conclusion, this study indicates a stronger short-
term analgesic effect on TMJ movement pain by
intra-articular administration of the 5-HT3 receptor
antagonist granisetron in patients with high levels of
circulating 5-HT.
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